TG Therapeutics, Inc.
Financials
Valuation Metrics
TG Therapeutics, Inc.'s Market Cap is $9.18B. At end of 2025 it was $4.26B. Ranked #940 of 3,118 in US market (top 30%), #298 of 1,474 on NASDAQ (top 20%), #46 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.18B | US#940/3,118 Sec#46/265 |
| Revenue | $800M | US#1,985/3,118 Sec#61/265 |
| Net Income | $441M | US#893/3,118 Sec#28/265 |
| Total Assets | $1.64B | US#2,205/3,118 Sec#65/265 |
| Net Assets | $604M | US#2,092/3,118 Sec#95/265 |
| Employees | 399 | US#2,327/3,118 Sec#93/265 |
| Value | ||
| P/E | 20.79x | US#1,199/3,118 Sec#34/265 |
| P/B | 15.19x | US#2,735/3,118 Sec#206/265 |
| PEG | 0.03x | US#93/3,118 Sec#7/265 |
| P/S | 11.48x | US#2,748/3,118 Sec#124/265 |
| EV/EBITDA | 70.43x | US#2,393/3,118 Sec#75/265 |
| FCF Yield | -0.01% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | 73.08% | US#62/3,118 Sec#5/265 |
| ROA | 26.93% | US#47/3,118 Sec#10/265 |
| Op. Margin | 17.05% | US#1,061/3,118 Sec#45/265 |
| Revenue Growth | 76.08% | US#137/3,118 Sec#39/265 |
| Earnings Growth | 630.24% | US#55/3,118 Sec#4/265 |
| Financial Health | ||
| Debt Ratio | 171.42% | US#1,629/3,118 Sec#191/265 |
| Total Debt | $754M | US#1,666/3,118 Sec#53/265 |
| FCF | $-560000.00 | US#2,305/3,118 Sec#87/265 |
| Cash | $483M | US#1,094/3,118 Sec#59/265 |
| Current Ratio | 4.27x | US#539/3,118 Sec#160/265 |
| Net Debt/EBITDA | 2.03x | US#1,332/3,118 Sec#57/265 |
| Performance | ||
| 1Y Return | 72.37% | US#237/3,118 Sec#50/265 |
| 1M Return | 10.43% | US#803/3,118 Sec#51/265 |
| From 52W High | -5.71% | US#55/3,118 Sec#4/265 |
| 1Y MDD | -21.83% | US#755/3,118 Sec#27/265 |
| Trading | ||
| Volume | 1,979,023 shares | US#808/3,118 Sec#69/265 |
| Trading Value | $121M | US#708/3,118 Sec#36/265 |
| Per Share | ||
| EPS | $2.88 | US#1,080/3,118 Sec#31/265 |
| BPS | $3.95 | US#2,357/3,118 Sec#139/265 |
Company Info
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.